Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma

Cancer

Volumn 82, Issue 6, 1998, Pages 1112-1117

  Fowler Jr , Jackson E ^a,b,c   Bigler, Steven A ^a   Kolski, John M ^a,b   Yee, David T ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Hormone therapy; Prostate neoplasms; Treatment outcomes

Indexed keywords

ACID PHOSPHATASE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RACE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CARCINOMA; COMBINED MODALITY THERAPY; COMORBIDITY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032521022     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1112::AID-CNCR15>3.0.CO;2-9     Document Type: Article

References (28)

1. Miller BA, Ries LAG, Hankey BF, Kosary CL, Harras A, Devesa SS, et al., editors. SEER Cancer Statistics Review, 1973-1990. NIH Pub. No. 93-2789. Bethesda, MD: National Cancer Institute, 1993.
2. McDowell GC, Johnson JW, Tenney DM, Johnson DE. Pelvic lymphadenectomy for staging clinically localized prostate cancer. Urology 1990;35:476-82.
3. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994;151: 1315-20.
4. Elfving P, Lundgren R. Pelvic lymphadenectomy as staging before definitive treatment of prostatic carcinoma. Scand J Urol Nephrol 1988; 110(Suppl):155-9.
5. Belt E, Schroeder FH. Total perineal prostatectomy for carcinoma of the prostate. J Urol 1972;107:91-6.
6. Boxer RJ, Kauffman JJ, Goodwin WE. Radical prostatectomy for carcinoma of the prostate: a review of 329 cases. J Urol 1977;117:208-18.
7. Hanks GE. External beam radiation for prostate cancer: patterns of care study in the United States. NCI Monogr 1988; 7: 85-94.
8. Perez CA, Pilepich MV, Garcia D, Simpson JR, Zivnuska F, Hederman MA, et al. Definitive radiation therapy in carcinoma of the prostate, localized to pelvis: experience at Mallinckrodt Institute of Radiology. NCI Monogr 1988;7:85-94.
9. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monogr 1988;7:165-70.
10. Fair WR, Sogani P, Whitmore WF. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71:1031-8.
11. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group. Urology 1995;45: 616-22.
12. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997;337:295-300.
13. Beahrs OH, Henson D, Hutter RVP, Kennedy BJ. Manual for staging of cancer. 4th edition. American Joint Committee on Cancer. Philadelphia: J. B. Lippincott, 1992.
14. Charlson ME, Pompei P, Alex KL, MacKenzi CR. A new method of classifying prognostic comorbidity in longitudinal studies: developments and validation. J Chronic Dis 1987;40:373-83.
15. Fowler JE, Terrell FL, Renfroe DL. Comorbidities and survival in men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996;156:1714-8.
16. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Longterm survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
17. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an anti-androgen (nilutamide). N Engl J Med 1989;321:413-8.
18. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79:1370-80.
19. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
20. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155:209-12.
21. Smith JA, Crawford ED, Lange PH, Lynch DF, Al-Juburi A, Bracken RB, et al. PSA correlation with response and survival in advanced carcinoma of the prostate. J Urol 1993;149:430A.
22. Tomlinson RL, Currie DP, Boyce WH. Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol 1977;117:85-7.
23. Fisher ES, Welch HG. The future of the Department of Veterans Affairs health care system. JAMA 1995;273:651-5.
24. National Center for Health Statistics. Vital statistics of the United States, 1990. Volume II. Mortality, Part A. Washington, DC: Public Health Service, 1994.
25. 125I implantation. Int J Radiat Oncol Biol Phys 1992;21:537-47.
26. Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:13-20.
27. Hanks GE. Optimizing the radiation treatment and outcome of prostatic cancer. Int J Radiat Oncol Biol Phys 1985; 11:1235-45.
28. Physician Data Querie Clinical Trial Database Number: National Cancer Institutes T94-0110.